专题:Melanoma and MAPK Pathways

This cluster of papers focuses on the mammalian MAP kinase signaling pathways, particularly their role in cancer, with a specific emphasis on melanoma. It covers the genetic mutations, targeted therapies, resistance mechanisms, and the impact of MAP kinase pathways on cell proliferation and immune response.
最新文献
Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation

article Full Text OpenAlex

Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany

article Full Text OpenAlex

FOXM1 induces therapy resistance and inhibits apoptosis in a variety of human cancers

article Full Text OpenAlex

Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial

article Full Text OpenAlex

Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C

article Full Text OpenAlex

Hallmarks of cancer—Then and now, and beyond

article Full Text OpenAlex

Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial

article Full Text OpenAlex

Society for Melanoma Research 22nd International Congress

article Full Text OpenAlex

Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma

article Full Text OpenAlex

Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update

article Full Text OpenAlex

近5年高被引文献
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

article Full Text OpenAlex 1704 FWCI165.354

Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040

article Full Text OpenAlex 1342 FWCI124.978

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

article Full Text OpenAlex 788 FWCI175.7418

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

article Full Text OpenAlex 732 FWCI108.0608

Cutaneous melanoma

review Full Text OpenAlex 625 FWCI137.9882

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

article Full Text OpenAlex 557 FWCI57.7266

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

article Full Text OpenAlex 493 FWCI37.7012

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

article Full Text OpenAlex 477 FWCI70.9057

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

article Full Text OpenAlex 462 FWCI45.0587

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

article Full Text OpenAlex 423 FWCI34.7533